Executive Director, Global Medical Affairs, GI

About Summit

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

• HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

• HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

• HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role:

The Executive Director, Medical Affairs, GI is a key leader and a subject matter expert responsible for shaping and executing the medical affairs strategy in GI cancers. This role oversees the development and implementation of medical affairs plans for lung-related indications, including launch excellence for multiple indications, lifecycle management, and scientific engagement. The Executive Director will collaborate within the medical affairs department and cross-functionally with Clinical Development, Regulatory Affairs, Commercial, and Market Access teams to ensure effective, compliant, and impactful disseminations of data, education on disease and therapeutic information and interactions with healthcare professionals, key opinion leaders, and decision makers. Recent, hands-on experience in GI cancers, either in clinical practice or within pharmaceutical companies, is essential.

Role and Responsibilities:

• Strategic Leadership
  • Develop and lead the US medical affairs strategy for GI cancers, ensuring alignment with global medical, clinical, and commercialization objectives.
  • Oversee the design, execution, and reporting of medical activities supporting the launch and lifecycle management
  • Foster a culture of high performance, collaboration, skills development, and scientific excellence across the medical affairs team.
• Team Leadership